The TOPIC trial (testing responsiveness to platelet inhibition on chronic antiplatelet treatment for acute coronary syndromes) randomized 646 ACS patients on DAPT to either switch to clopidogrel or continue the newer P2Y12 inhibitor one month after PCI. This evidence concerns the gene P2RY12 and acute coronary syndrome.